Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Whole body amyloid deposition imaging by 123I-SAP scintigraphy
Amyloidosis is the name of a group of diseases characterized by extracellular deposition of amyloid fibrils. Deposition of amyloid can be localized or systemic. The 123I-SAP-scan can be used to image extent and distribution of amyloid deposition in patients with systemic AA, AL and ATTR amyloidosis. Images are assessed in a semi-quantitative way by comparing each organ directly or indirectly to the normal blood-pool distribution. Considerable variation is observed between the findings on 123I-SAP-scan and clinical manifestations of organ disease. Regardless, the 123I-SAP-scan still provides both an impression...
Ronald van Rheenen, Andor Glaudemans, Bouke Hazenberg
The role of radiolabeled anti-TNFα monoclonal antibodies for diagnostic purposes and therapy evaluation
Radiolabelled cytokines and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have excellent diagnostic potential for imaging of patients with chronic inflammatory diseases. One of the key cytokines involved in the process of inflammation is tumor necrosis factor alpha (TNFα). With the introduction of anti-TNFα monoclonal antibodies over the past decade, treatment of inflammatory diseases has evolved, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing destruction....
A. W.J.M. Glaudemans, R. A.J.O. Dierckx, C. G.M. Kallenberg, K. L. Anzola Fuentes
The role of radiolabelled anti-TNF alpha monoclonal antibodies for diagnostic purposes and therapy evaluation
Radiolabelled cytokines and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have excellent diagnostic potential for imaging of patients with chronic inflammatory diseases. One of the key cytokines involved in the process of inflammation is tumor necrosis factor alpha (TNF alpha). With the introduction of anti-TNF alpha monoclonal antibodies over the past decade, treatment of inflammatory diseases has evolved, which allowed remarkable advances in controlling signs and symptoms of inflammation and in...
A. W. J. M. Glaudemans, R. A. J. Dierckx, C. G. M. Kallenberg, K. L. Anzola Fuentes
Molecular imaging in atherosclerosis
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-010-1406-4
Atherosclerosis is the major cause of cardiovascular disease, which still has the leading position in morbidity and mortality in the Western world. Many risk factors and pathobiological processes are acting together in the development of atherosclerosis. This leads to different remodelling stages (positive and negative) which are both associated with plaque physiology and clinical presentation. The different remodelling stages of atherosclerosis are explained with their clinical relevance. Recent advances in basic science have established that atherosclerosis is not only a lipid storage disease, but that also inflammation has...
Andor W. J. M. Glaudemans, Riemer H. J. A. Slart, Alessandro Bozzao, Elena Bonanno, Marcello Arca, Rudi A. J. O. Dierckx, Alberto Signore
The role of radiolabeled anti-TNFα monoclonal antibodies for diagnostic purposes and therapy evaluation
Radiolabelled cytokines and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have excellent diagnostic potential for imaging of patients with chronic inflammatory diseases. One of the key cytokines involved in the process of inflammation is tumor necrosis factor alpha (TNFα). With the introduction of anti-TNFα monoclonal antibodies over the past decade, treatment of inflammatory diseases has evolved, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing destruction....
A. W.J.M. Glaudemans, R. A.J.O. Dierckx, C. G.M. Kallenberg, K. L. Anzola Fuentes